NASDAQ:TNYA

Tenaya Therapeutics (TNYA) Stock Forecast, Price & News

$7.59

-0.05 (-0.65%)

(As of 01:11 PM ET)

Compare

Today's Range: $7.48
▼
$7.70
50-Day Range: $2.64
▼
$7.64
52-Week Range: $1.64
▼
$7.95

Volume: 200,284 shs
Average Volume: 538,660 shs
Market Capitalization: $507.54 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Tenaya Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 148.7% Upside
$18.75 Price Target
Short Interest: Bearish
5.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$17,625 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.98) to ($2.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

743rd out of 980 stocks

Biological Products, Except Diagnostic Industry

117th out of 163 stocks

3.5

Analyst's Opinion

Consensus Rating
Tenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.75, Tenaya Therapeutics has a forecasted upside of 148.7% from its current price of $7.54.
Amount of Analyst Coverage
Tenaya Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.04% of the float of Tenaya Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Tenaya Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tenaya Therapeutics has recently increased by 30.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tenaya Therapeutics does not currently pay a dividend.
Dividend Growth
Tenaya Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TNYA.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Tenaya Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 9 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tenaya Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $17,625.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
34.24% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tenaya Therapeutics are expected to decrease in the coming year, from ($1.98) to ($2.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tenaya Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tenaya Therapeutics is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tenaya Therapeutics has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive TNYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNYA Stock News Headlines

June 3, 2023 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Brokerages

June 2, 2023 | fool.com

Tenaya Therapeutics (NASDAQ: TNYA)

June 5, 2023 | Edge On The Street (Ad)

AI industry Is Exploding! New Breakthrough Expected this Summer

Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.

May 30, 2023 | finance.yahoo.com

With 35% stake, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) seems to have captured institutional investors' interest

May 16, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for Tenaya Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:TNYA)

May 15, 2023 | finance.yahoo.com

Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade

May 14, 2023 | americanbankingnews.com

Chardan Capital Trims Tenaya Therapeutics (NASDAQ:TNYA) Target Price to $23.00

May 12, 2023 | msn.com

Chardan Capital Maintains Tenaya Therapeutics (TNYA) Buy Recommendation

June 5, 2023 | Edge On The Street (Ad)

AI industry Is Exploding! New Breakthrough Expected this Summer

Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.

May 12, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Tenaya Therapeutics

May 12, 2023 | marketwatch.com

8-K: Tenaya Therapeutics, Inc.

May 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Tenaya Therapeutics (TNYA) Buy Recommendation

May 11, 2023 | finance.yahoo.com

Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why

May 11, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Tenaya Therapeutics (TNYA)

May 10, 2023 | finance.yahoo.com

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $19.00 Consensus PT from Analysts

May 3, 2023 | finance.yahoo.com

We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully

May 3, 2023 | finance.yahoo.com

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

May 2, 2023 | marketwatch.com

Tenaya Therapeutics Gets FDA Fast-Track Designation for TN-201 >TNYA

May 2, 2023 | finance.yahoo.com

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

May 1, 2023 | msn.com

Unusual Call Option Trade in Tenaya Therapeutics (TNYA) Worth $38.40K

April 21, 2023 | benzinga.com

Tenaya Therapeutics Stock (NASDAQ:TNYA), Dividends

April 19, 2023 | finance.yahoo.com

These 2 ‘Strong Buy’ Penny Stocks Could Rally to $40 (or More), Says Piper Sandler

April 14, 2023 | americanbankingnews.com

Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $19.00

April 10, 2023 | seekingalpha.com

Tenaya Therapeutics Has Been An Early Stage Company For Too Long

March 9, 2023 | markets.businessinsider.com

LifeSci Capital Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)

March 9, 2023 | finanznachrichten.de

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

See More Headlines

TNYA Price History

30 days | 90 days | 365 days | Advanced Chart

TNYA Company Calendar

Last Earnings: 3/08/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TNYA
CUSIP: N/A
CIK: 1858848
Web: www.tenayatherapeutics.com
Phone: 650-825-6990
Fax: N/A
Employees: 106
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.75
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +135.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -56.59%
Return on Assets: -49.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.01
Quick Ratio: 8.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.64 per share
Price / Book: 2.10

Miscellaneous

Outstanding Shares: 66,870,000
Free Float: 43,974,000
Market Cap: $510.89 million
Optionable: Not Optionable
Beta: 2.44

Key Executives

Mr. Faraz Ali M.B.A. (Age 49)
CEO, Sec. & Director
Comp: $710.77k

Dr. Deepak Srivastava M.D. (Age 55)
Scientific Founder, Chairman of Scientific Advisory Board & Director
Comp: $18.15k

Ms. Leone D. Patterson M.B.A. (Age 59)
Chief Financial & Bus. Officer
Comp: $448.55k

Dr. Whittemore G. Tingley M.D. (Age 54)
PH.D., Chief Medical Officer
Comp: $551.18k

Dr. Eric N. Olson Ph.D.
Scientific Founder & Member of Scientific Advisory Board

Dr. Bruce R. Conklin
Scientific Founder

Dr. Saptarsi Haldar M.D.
Scientific Founder

Dr. Sheng Ding
Scientific Founder

Dr. Benoit G. Bruneau Ph.D.
Scientific Founder

Dr. Kee-Hong Kim Ph.D. (Age 56)
Chief Technology Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TNYA Stock - Frequently Asked Questions

Should I buy or sell Tenaya Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNYA shares.
View TNYA analyst ratings or view top-rated stocks.
What is Tenaya Therapeutics' stock price forecast for 2023?: 6 Wall Street research analysts have issued 12-month target prices for Tenaya Therapeutics' shares. Their TNYA share price forecasts range from $13.00 to $23.00. On average, they anticipate the company's stock price to reach $18.75 in the next twelve months. This suggests a possible upside of 145.4% from the stock's current price.
View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts.
How have TNYA shares performed in 2023?: Tenaya Therapeutics' stock was trading at $2.01 at the beginning of 2023. Since then, TNYA shares have increased by 280.1% and is now trading at $7.64.
View the best growth stocks for 2023 here.
Are investors shorting Tenaya Therapeutics?: Tenaya Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,060,000 shares, an increase of 30.4% from the April 30th total of 1,580,000 shares. Based on an average daily trading volume, of 642,700 shares, the days-to-cover ratio is presently 3.2 days. Approximately 5.0% of the shares of the stock are short sold.
View Tenaya Therapeutics' Short Interest.
When is Tenaya Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our TNYA earnings forecast.
How were Tenaya Therapeutics' earnings last quarter?: Tenaya Therapeutics, Inc. (NASDAQ:TNYA) released its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.05.
What ETF holds Tenaya Therapeutics' stock ?: BlackRock Future Health ETF holds 354 shares of TNYA stock, representing 0.04% of its portfolio.

When did Tenaya Therapeutics IPO?: (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.
What is Tenaya Therapeutics' stock symbol?: Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA."
Who are Tenaya Therapeutics' major shareholders?: Tenaya Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.56%), FMR LLC (5.62%), BlackRock Inc. (4.17%), Regents of The University of California (1.44%), Geode Capital Management LLC (1.18%) and State Street Corp (0.74%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Group Gp Lp Column III and Timothy Hoey.
View institutional ownership trends.
How do I buy shares of Tenaya Therapeutics?: Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tenaya Therapeutics' stock price today?: One share of TNYA stock can currently be purchased for approximately $7.64.
How much money does Tenaya Therapeutics make?: Tenaya Therapeutics (NASDAQ:TNYA) has a market capitalization of $510.89 million. The company earns $-123,670,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis.
How many employees does Tenaya Therapeutics have?: The company employs 106 workers across the globe.
How can I contact Tenaya Therapeutics?: The official website for the company is www.tenayatherapeutics.com. The company can be reached via phone at 650-825-6990 or via email at investors@tenayathera.com.

This page (NASDAQ:TNYA) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial